TABLE 1.
Patient characteristics according to the treatment protocol
| Total | CPaI | SScI | P value | |
|---|---|---|---|---|
| Number of patients | 256 | 45 | 211 | |
| Age, y | ||||
| Median (range) | 66 (50‐87) | 66 (54‐83) | 66 (50‐87) | .635 |
| T stage | ||||
| T1b | 0 | 0 | 0 | .097 |
| T1c | 89 (35%) | 17 (38%) | 73 (35%) | |
| T2a | 66 (26%) | 5 (11%) | 58 (27%) | |
| T2b | 13 (5%) | 3 (7%) | 7 (3%) | |
| T2c | 34 (13%) | 6 (13%) | 34 (16%) | |
| T3a | 44 (17%) | 13 (29%) | 31 (15%) | |
| T3b | 10 (4%) | 2 (4%) | 8 (4%) | |
| Gleason score | ||||
| 6 | 66 (26%) | 11 (24%) | 55 (26%) | .150 |
| 7 | 115 (45%) | 15 (33%) | 100 (47%) | |
| 8 | 27 (11%) | 8 (17%) | 19 (9%) | |
| 9 | 48 (19%) | 11 (24%) | 17 (8%) | |
| 10 | 0 | 0 | 0 | |
| Pretreatment PSA level, ng/mL | ||||
| <10 | 157 (61%) | 21 (47%) | 136 (64%) | .013 |
| 10‐20 | 64 (25%) | 12 (27%) | 52 (25%) | |
| >20 | 35 (14%) | 12 (27%) | 23 (11%) | |
| Risk group | ||||
| Low | 41 (16%) | 9 (20%) | 32 (15%) | .018 |
| Intermediate | 111 (43%) | 11 (24%) | 100 (47%) | |
| High | 104 (41%) | 25 (56%) | 79 (37%) | |
Abbreviations: ADT, androgen deprivation therapy; CPaI, clinical protocol using passive irradiation; SScI, standard therapy protocol using scanning irradiation.